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Vein graft adaptation to the arterial circulation entails many changes at the 
cellular/molecular levels, including both cell proliferation and extracellular matrix (ECM) 
deposition/remodeling, resulting in thickening of the vein wall, and in excessive cases, 
pathological neointimal hyperplasia. Eph-B4 is a receptor tyrosine kinase and embryonic 
determinant of veins that, when stimulated, has been shown by our lab to decrease vein 
graft wall thickening. We hypothesize that among other mechanisms, Eph-B4 exerts this 
effect through modulating extracellular matrix production and/or degradation, and that 
Eph-B4 interacts directly with eNOS to mediate some of its downstream effects. 
 
Methods 
Mouse Embryonic Fibroblasts (MEFs) were stimulated with 2 ug/ml Ephrin-
B2/Fc, the stimulatory ligand for Eph-B4. To determine mRNA changes, cell lysates 
were collected after various stimulation periods, followed by mRNA purification and RT-
PCR for each specified gene of interest. Similarly, mRNA was also extracted from 
human saphenous veins in culture. For Western Blot and Zymography, both cell lysates 
and conditioned media (secreted proteins) were collected after various periods of 
stimulation. In vivo, 4 week old vein graft sections from WT and Eph-B4 knockout mice, 
or from Ephrin-B2/Fc stimulated or unstimulated mice, were stained with Masson’s 
Trichrome, and the total area of blue staining surrounding the vein graft was quantified to 
determine graft wall collagen content. For eNOS experiments, either Eph-B4 or Y774F 
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mutant Eph-B4 was transfected into COS cells, followed by Ephrin-B2/Fc stimulation for 
1-60 minutes and determination of eNOS phosphorylation utilizing Western Blot. 
 
Results 
mRNA expression of Collagen I, Collagen III, Matrix Metalloproteinase 2 
(MMP2), MMP9, MMP14, elastin, Tissue Inhibitor of Metalloproteinases 1 (TIMP1), 
and TIMP2 were not affected by Eph-B4 stimulation. mRNA expression of Collagen 1 in 
human saphenous veins in culture was not affected by Eph-B4 stimulation. Eph-B4 had 
no effect on MMP2 and MMP9 cellular protein levels as detected by Western Blot, and 
no effect on MMP2 protein activity as detected by zymography in cell lysates and 
conditioned media. Masson’s Trichrome staining of mice vein graft sections revealed that 
most of the collagen within the vein graft was within the adventitia. There were no 
differences in either collagen content or lumen circumference between vein grafts from 
WT and Eph-B4 KO mice, and between control mice and mice stimulated with Ephrin-
B2/Fc. Dual transfection of cells with endothelial nitric oxide synthase (eNOS) and Eph-
B4 resulted in increased eNOS phosphorylation; Eph-B4 stimulation further increased 
eNOS phosphorylation. Y774 is not crucial to Eph-B4’s effects on eNOS. 
 
Conclusions 
Eph-B4 likely does not exert its effects on decreasing vein graft thickening 
through directly modulating ECM deposition and remodeling. Eph-B4 likely exerts its 
effects through other mechanisms such as modulating cellular proliferation within the 
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vein graft wall. Eph-B4 likely mediates at least some of its downstream effects through a 
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Vein Graft Adaptation 
Despite significant advancements in medical knowledge over the recent years, 
cardiovascular disease remains the leading cause of death in the United States. For 
advanced cardiovascular disease, bypass surgery with autologous vein is a common and 
important treatment, both peripherally for peripheral vascular disease and centrally for 
coronary artery disease (1, 2). However, the adaptation of the vein to this new arterial 
hemodynamic environment, which includes increased flow, pressures, and oxygen 
tension, is still not well understood. Successful adaptation plays a crucial role in the long-
term function and patency of the vein graft and is characterized by venous dilation and 
wall thickening. On the other hand, unsuccessful adaptation may involve insufficient or 
excessive occurrence of these same processes, resulting in thrombosis, stenosis, 
subsequent patient morbidity, and significant healthcare costs (3, 4). 
 
Figure 1. Previous work done by our lab demonstrating extracellular matrix deposition 
within Trichrome stains of rat vein grafts. (1) 
 
Long-term failure rates for vein grafts are significant, with 1 year primary patency 
rates reported to range from 80% to as low as 60% (2, 5-7). The most common 
mechanism of vein graft failure is the over-exuberant thickening of the vein graft wall 
beyond the level necessary for normal adaptation, known as neointimal hyperplasia 
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(NIH), without corresponding wall dilation, leading to decreased luminal size and 
stenosis. The molecular pathways contributing to this mechanism are complex. 
Endothelial denudation and disruption of endothelial signaling play an important role, 
while various other mediators such as oxidative stress and the inflammatory and 
coagulation cascades also contribute to wall thickening and failure. Eventually, these 
pathways result in modulation of extracellular matrix deposition and remodeling (Figure 
1), mediated by transforming growth factor-β (TGF-β) and the matrix metalloproteinases 
(MMPs), respectively, and cell proliferation and migration, mediated by a variety of 
cytokines and growth factors such as VEGF, PDGF, bFGF, IGF, and other related 
molecules (3, 4, 8-14).  
Over the years, our understanding of this failure mechanism has increased 
substantially, leading to a multitude of targeted experimental therapies to better control 
this process in order to improve the long-term outcomes of vein graft procedures (3, 4, 
15, 16). However, these therapies have largely not been fruitful, as demonstrated by the 
disappointing results of the recent PREVENT III trials focusing on the E2F antagonist 
edifoligide (2, 15). As a result, there are still no successful methods to limit NIH, and the 
long-term failure rate of vein grafts remains high.  
 
The Receptor Tyrosine Kinase Eph-B4 
Recently, molecular distinctions between arteries and veins have been identified, 
including their differing genetic environments and embryologic determinations of 
identity (17). Especially important are the roles of Eph-B4 and its ligand Ephrin-B2, both 
part of the Eph (erythropoietin-producing hepatocellular carcinoma) family, the largest 
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family of receptor tyrosine kinases. Embryologically, Ephrin-B2 is a genetic determinant 
of arteries, while Eph-B4 is a genetic determinant of veins. However, while both are 
thought to remain markers of vascular identity, it is currently unknown whether they 
remain active in influencing the plasticity of arteries and veins even in adulthood.(1, 4, 
18-21)  
Our lab has sought to determine whether alterations in the expression of Eph-B4 
and Ephrin-B2 may influence vein graft adaptation to the arterial environment. We have 
shown that vein graft adaptation in humans is characterized by loss of Eph-B4 expression 
without corresponding increase in Ephrin-B2 expression, signifying a loss of venous 
identity but without a corresponding gain in arterial identity (1). Furthermore, we have 
shown that increased expression of Eph-B4 may negatively inhibit neointimal 
hyperplasia, suggesting that Eph-B4 continues to play an important role in vessel 
plasticity and implicating Eph-B4 as an important molecular target for the 
pharmacological inhibition of vein graft failure due to neointimal hyperplasia (22). 
Like all Eph receptors, Eph-B4 activation is strictly regulated, and occurs through 
auto-phosphorylation. Upon interacting with its ligand (Ephrin-B2) on the cellular 
surface, two inactive Eph-B4 kinase domains are brought together and dimerized. 
Immediately afterwards, the Eph-B4 dimer catalyzes the autophosphorylation of its own 
cytoplasmic domains, resulting in the commencement of its downstream effects. In 
addition to dimerization, clustering of many Eph-B4 domains leading to oligomerization 
may also occur (23). 
However, the downstream mechanisms by which stimulation of Eph-B4 leads to 
decreased vein graft thickening is still unclear, and the elucidation of this mechanism 
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may open up new avenues of research and define novel ways to target this pathological 
mechanism of vein graft failure. Preliminary work in our lab has demonstrated that 
tyrosine 774 may be the tyrosine critical for Eph-B4 function, as mutations in Y774 lead 
to abolishment of Eph-B4’s ability to phosphorylate the kinase Akt, one of the possible 
downstream effectors of Eph-B4 (24) (Figure 2). Finally, since Eph-B4 is upstream of 
the E2F pathway, modulation of Eph-B4 may provide significant therapeutic value, 
unlike the PREVENT trials. 
 
Figure 2. Preliminary data from our lab demonstrating loss of Eph-B4’s ability to induce 
phosphorylation of Akt after stimulation with Ephrin-B2/Fc (p = 0.0284). 
 
The Role of Extracellular Matrix in Vein Graft Adaptation 
Although vascular smooth muscle cell proliferation and migration plays a large 
role in neointimal hyperplasia, coordinated extracellular matrix (ECM) deposition and 
remodeling is similarly critical. Removal and remodeling of existing extracellular matrix 
is necessary to allow venous dilation and cellular migration, while additional matrix 
deposition contributes to overall wall thickening (25). Westerband et al. demonstrated 
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that cellular proliferation and apoptosis in a vein graft is maximal in the first week after 
the procedure but is minimal afterwards, suggesting that any additional changes in wall 
thickness is likely due to extracellular matrix deposition (13). Additionally, continued 
increases in wall stiffness up to 6 months after vein graft implantation provides further 
evidence for the importance of matrix deposition during adaptation (26, 27). 
Matrix deposition within vein graft walls is mediated by TGF-β, a cytokine 
produced from a variety of cell types, including inflammatory, endothelial, and smooth 
muscle cells (28). Upregulated expression of TGF-β and TGF-β receptor occurs soon 
after vein graft creation, while perioperative antisense inhibition of TGF-β expression 
leads to significant reduction in vein graft neointimal area (28, 29).  Upregulation of 
TGF-β mRNA is further shown to be correlated with increased mRNA expression of both 
collagen I and collagen III (30). Jiang et al. demonstrated within rabbit vein grafts that 
progressive increases in neointimal mass up to 6 months after vein graft implantation is 
associated with minimal further cell proliferation, a decreased overall cell density, and a 
significantly increased proteoglycan content that occurs along with increased signaling of 
TGF-β and its downstream effector connective tissue growth factor (CTGF), again 
confirming the important contributions of extracellular matrix deposition to neointimal 
hyperplasia (25). 
While TGF-β mediates ECM deposition, the matrix metalloproteinases regulate 
ECM remodeling, inducing the removal of collagen and elastin and possibly even the 
degradation of the internal elastic lamina to allow venous dilation and cell migration. The 
MMP family has been extensively studied and is stimulated by myriad factors that play a 
role during vein graft adaptation, including oxidative stress, inflammation, flow, stretch, 
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and even surgical injury itself (16, 31-33). Of these, MMP-2 and MMP-9 have been 
studied most extensively. Both demonstrate increased activity within the neointima of 
vein grafts soon after implantation but decline after 3-6 months, suggesting their 
importance to early vein wall remodeling and cell migration (25, 32, 34). Additionally, 
the surgical preparatory process itself, which includes adventitial stripping, ligation, and 
distension, has also been shown to increase MMP-2 and MMP-9 within the venous wall 
(35). A related molecule, MT1-MMP (MMP-14), an MMP-2 upstream activator, is also 
upregulated following vein graft implantation (34). Another related molecule, elastase, 
has also been shown to be upregulated, while elafin, an inhibitor of elastase, protects 
against neointimal hyperplasia in vein grafts (36). Meanwhile, TIMPs (Tissue Inhibitor of 
Metalloproteinase) are the main regulators of MMP activity, although their roles during 
vein graft adaptation is still unclear. TIMP-2 has been shown to be decreased early, 
followed by a return to baseline, while TIMP-1 has been shown to be upregulated (29, 
34). Meanwhile, stimulation of TIMP-3 decreases neointimal hyperplasia (37). 
 
The Role of eNOS in Vein Graft Adaptation 
Surgical injury and irrigation, in addition to the new high/turbulent flow and high 
pressure hemodynamic environment, result in endothelial injury and denudation; 
denudation of the endothelium in a vessel may lead to exposure of the subendothelial 
collagen, loss of barrier function, and activation of the inflammatory and coagulation 
cascades (3, 9). Within vein grafts, endothelial denudation occurs within an hour after 
graft implantation, and the endothelial layer is not fully regenerated until 2 weeks after 
the procedure (8, 38). As the endothelium is thought to play a major role in regulating 
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both the caliber and adaptation of the vein, disruption of endothelial signaling in this 
manner potentially impairs the normal adaptive process, resulting in neointimal 
hyperplasia.  
Among the vasoactive signals released by the vascular endothelium in responses 
to changes in its hemodynamic environment, nitric oxide (NO) has been the most 
extensively studied in the pathophysiology of vein graft adaptation. NO is created from 
endothelial nitric oxide synthase (eNOS), which is expressed by vascular endothelial 
cells, and is a potent vasodilator with additional anti-inflammatory, anti-thrombotic, and 
anti-proliferative properties (3, 4, 9). NO has been shown to limit macrophage 
infiltration, cell proliferation, and subsequent neointimal thickening within vein grafts 
(39, 40). Similarly, stimulation of eNOS and its related molecule inducible nitric oxide 
synthase (iNOS) may both inhibit neointimal hyperplasia, with iNOS additionally shown 
to inhibit adventitial thickening (40-42). Furthermore, surgical manipulation involves 
oxidative stress to the vein grafts during removal from the adventitial bed, disruption of 
the vasa vasorum, and subsequent ischemia-reperfusion. Superoxide, in particular, can 
deplete NO, leading to further disruption of its downstream effects (3, 43, 44). Finally 
and most importantly, preliminary experiments performed in our lab have suggested that 
Eph-B4 may play a significant role in eNOS signaling, as stimulation of Eph-B4 in 
mouse lung endothelial cells (MLECs) lead to two distinct peaks of eNOS 





Figure 3. Preliminary data from our lab demonstrating Eph-B4 stimulation of eNOS 




HYPOTHESIS AND SPECIFIC AIMS 
 
 
Although we have demonstrated that stimulation of Eph-B4 reduces vein wall 
thickening during vein graft adaptation, the mechanism by which it accomplishes this 
function is still unclear. We believe that the elucidation of this mechanism will be 
integral in the search for new pharmaceutical targets based on Eph-B4 to manipulate 
vessel identity, control neointimal hyperplasia, and improve the long-term function of 
vein grafts in the future. 
Given the importance of extracellular matrix deposition on vein graft adaptation, 
we hypothesize that Eph-B4, directly or indirectly, reduces vein wall thickening at 
least partly through decreasing extracellular matrix deposition within the venous 
wall. Furthermore, given that our preliminary data suggested that Eph-B4 may stimulate 
eNOS phosphorylation, we hypothesize that Eph-B4 interacts directly with eNOS to 
stimulate its phosphorylation and mediate some of its downstream effects. 
 
Aim I: We will determine whether stimulation of Eph-B4 alters ECM 
deposition and remodeling. With in vitro cell culture experiments, we will stimulate 
cells with the ligand to the Eph-B4 receptor, Ephrin-B2, and quantify the mRNA and 
protein expression of ECM-related products compared to unstimulated cells. With in vivo 
mouse vein graft experiments, we will determine the effect of Eph-B4 stimulation or 
knockout on the ECM deposition within the walls of mouse vein grafts. Finally, in ex 
vivo experiments, we seek to determine the effect of Eph-B4 stimulation on collagen 
expression in human saphenous veins in culture. 
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Aim II: We will determine whether Eph-B4 directly interacts with eNOS to 
mediate some of its downstream effects. Given that our preliminary data suggested that 
Eph-B4 may mediate some of its effects either directly or indirectly through eNOS 
phosphorylation, we will determine whether Eph-B4 interacts directly with eNOS. We 
will transfect Eph-B4 and eNOS into a cell line that has no inherent expression of either 
Eph-B4 or eNOS and thus likely little of the cellular machinery associated with either. 
Any alterations of eNOS phosphorylation after Eph-B4 stimulation in this context will 
suggest a direct interaction between Eph-B4 and eNOS. Finally, if a direct interaction is 
established in this way, we will repeat this experiment with Eph-B4 Y774F to determine 






MATERIALS AND METHODS 
 
 
Antibodies and Reagents 
Primary antibodies included: mouse Eph-B4 (R&D systems), mouse Ephrin-B2 
(Abcam), mouse MMP2 (Cell Signaling Technology), mouse MMP9 (Abcam), HA-tag 
(Santa Cruz Biotechnology), total eNOS (Abcam), phospho-eNOS (Abcam), GAPDH 
(Cell Signaling Technology). Secondary antibodies included: HRP-conjugated anti-rabbit 
IgG (Cell Signaling Technology), HRP-conjugated anti-goat IgG (Cell Signaling 
Technology). 
For stimulation experiments, mouse Ephrin-B2/Fc, IgG/Fc, and cd6/Fc chimeras 
(R&D Systems) were used for mouse cell culture and vein graft experiments, while 
human Ephrin-B2/Fc chimera (R&D Systems) was used for human vein culture 
experiments. 
 
Cell Culture (MEF, HUVEC, MLEC, COS) and Eph-B4 Stimulation 
MEFs (Mouse Embryonic Fibroblasts) and COS cells (monkey kidney fibroblast-
like cell line) were cultured on high-glucose DMEM (Dulbecco’s modified Eagle’s 
medium) (Gibco Life Technologies) supplemented with 10% fetal bovine serum (FBS) 
(Gibco Life Technologies), L-glutamine, and penicillin/streptomycin. MLECs (Mouse 
Lung Endothelial Cells) and HUVECs (Human Umbilical Vein Endothelial Cells) were 
cultured in EBM-2 (Endothelial Basal Media-2) (Lonza) and supplemented with 15% 
FBS, L-glutamine, penicillin/streptomycin, and EGM-2 Bulletkit from Lonza, per 
manufacturer’s recommendations. HUVECs used for experiments were at a maximum 
passage number of 6. 
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Prior to stimulation experiments, cells were plated on 6 well plates, grown to 
confluence, and starved in serum free media for 24 hours. Following starvation, cells 
were stimulated with either 2 ug/ml mouse Ephrin-B2/Fc or 2 ug/ml mouse IgG/Fc 
(negative control) (R&D Systems) in serum free media, for the designated amount of 
time, after which either the cell lysates or the conditioned media were collected.  
 
RNA Extraction and qPCR (primers) 
After completion of stimulation experiments, cells were lysed directly from their 
culture plates with Buffer RLT and RNA was extracted using the RNeasy kit (QIAGEN) 
and utilizing DNaseI for DNA digestion, per manufacturer’s protocol. RNA 
concentration was measured with Nanodrop and RNA quality was checked through the 
260/280 ratio, followed by normalization of RNA concentration. cDNA was then created 
through reverse transcription, utilizing SuperScript III First-Strand Synthesis Supermix 
(Invitrogen) per manufacturer’s protocol. cDNA amplification utilized real-time, 
quantitative PCR with SYBR Green Supermix (Bio-Rad), with all samples normalized to 
GAPDH as the housekeeping gene. Melting curve analysis and gel electrophoresis was 
used to confirm primer efficiency and specificity, respectively.  
mRNA was isolated from mouse muscle tissue from TRIzol reagent (Invitrogen), 
followed by extraction utilizing the RNeasy kit as described above. Mouse muscle tissue 
mRNA extraction and PCR were performed by Dr. Kota Yamamoto. 
Primers utilized for mouse cell culture experiments were: Col1a1 (Collagen I): 
forward, 5’-CACCTGGTCCACAAGGTTTC-3’, reverse, 5’-
ACCATCCAAACCACTGAAGC-3’. Col3a1 (Collagen III): forward, 5’-
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CAGGAGAAAATGGGAAACCA-3’, reverse, 5’-GTCCAGCTCCACCTCTAGCA-3’. 
MMP2: forward, 5’-CAGGGCACCTCCTACAACAG-3’, reverse, 5’-
ACTTGTTGCCCAGGAAAGTG-3’. MMP9: forward, 5’-
CATTCGCGTGGATAAGGAGT-3’, reverse, 5’-ACCTGGTTCACCTCATGGTC. 
MMP14: forward, 5’-CCCTTTTACCAGTGGATGGA-3’, reverse, 5’-
TTTGGGCTTATCTGGGACAG-3’. Elastin: forward, 5’-
GAGGTTTAGTGCCTGGTGGA-3’, reverse, 5’-ATATGTCGGGATGCCAACTC-3’. 
TIMP1: forward, 5’-GCATCTGGCATCCTCTTGTT-3’, reverse, 5’-
CATTTCCCACAGCCTTGAAT-3’. TIMP2: forward, 5’-
AAGCAGTGAGCGAGAAGGAG-3’, reverse, 5’-TTCTTTCCTCCAACGTCCAG-3’. 
GAPDH: forward, 5’-AATGTGTCCGTCGTGGATCTGA-3’, reverse, 5’-
AGTGTAGCCCAAGATGCCCTTC-3’. 
Primers utilized for human vein graft culture experiments were: Col1a1: forward, 
5’-CTGGTCCTGATGGCAAAACT-3’, reverse, 5’-AGCTCCAGCCTCTCCATCTT-3’. 
GAPDH: forward, 5’-GAGAAGGCTGGGGCTCATTT-3’, reverse, 5’-
AGTGATGGCATGGACTGTGG-3’. 
 
Human Saphenous Vein Culture 
Remnants of excess saphenous vein (n=7) from coronary bypass procedures were 
procured, per HIC protocol #9908011041, cut into cross-sectional rings, and placed into 
culture (RPMI 1640, Gibco, with 30% FBS, 1% L-glut, pen/strep) at 37°. Each vein was 
divided into 3 segments. After blinding, one segment from each vein was cultured but 
unstimulated for 14 days, one segment was stimulated with 2ug/ml Ephrin-B2/Fc (R&D 
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Systems), and one segment was immediately processed as Day 0 without culturing. 
Samples were the frozen in optimal cutting temperature compound (OCT, Tissue-Tekl 
Sakura Finetek), followed by homogenization and RNA purification using RNeasy Mini 
Kit (Qiagen), per manufacturer’s protocol, and finally qPCR with primers as described 
previously. All human saphenous vein culture steps prior to qPCR were performed by 
fellow lab member Daniel Wong, as detailed in his own thesis dissertation. All qPCR 
data for each sample (stimulated, unstimulated) was normalized to GAPDH as a 
housekeeping gene, and then normalized to the corresponding Day 0 sample. 
 
Quantification of Collagen-related Protein expression 
For Western Blots, cell lysates were collected from the cell culture plates with 
RIPA buffer after the specified stimulation times, followed by sonication of each sample 
for disruption of cell membranes. Protein concentrations were measured utilizing BioRad 
Protein Assay and normalized. Equal amounts of protein from each sample were loaded 
onto 10% SDS-PAGE gels, followed by transfer for Western blot. The membranes were 
then incubated with the specified antibodies, overnight for primary, and 1 hour for 
secondary, as described under Antibodies and reagents, followed by film exposure and 
development. Quantitative analysis of western blot bands was performed by densitometry 
with ImageJ. Cell counts, when necessary, were performed with a haemocytometer and 
Trypan Blue. 
For quantification of total collagen expression, we utilized the Sircol Collagen 
Assay (Biocolor Life Science Assays). For each n, 3-7 replicates were used. Briefly, cells 
were stimulated as above, except stimulation occurred immediately when cultured to 
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account for collagen deposition in first 24 hours. Afterwards, microwell plates were 
subject to 24 hours of collagen extraction in 0.1mg/ml of pepsin (Sigma) in 0.5 M acetic 
acid at 4º, followed by isolation of collagen with the Sircol Assay, per manufacturer’s 
protocol. Final collagen quantification was performed with a microwell plate reader at a 
wavelength of 550nm, corresponding to the peak absorption of the Sirius Red-based dye. 
Each measurement n (total n=6) was the mean of 3-7 replicates. As the same 
concentration of cells was used in all the replicates of a given n, measurements for both 
control and stimulated groups were normalized to that of the control group. 
 
Gelatin Zymography 
After the specified stimulation times, conditioned media from the cell culture 
plates were collected and added to equal volumes of Laemmli Sample Buffer (BioRad). 
The resulting mixtures were then ran through 10% SDS-PAGE gels with 10% porcine 
skin gelatin (Sigma). Gels were then renatured with renaturing buffer (2.5% Triton-X in 
water v/v) for 30 minutes, followed by incubation at 37° for 2-4 hours in developing 
buffer (per Millipore Zymography protocol). Finally, gels were stained with .25% 
Coomassie Blue-R250, followed by destaining with destaining solution (per Millipore 
Zymography protocol). Quantitative analysis of zymography bands was performed by 
densitometry with ImageJ. 
 
Histological Quantification of Collagen in Mouse Vein Grafts 
Mouse vein graft sections were obtained from prior lab members, per their 
previous surgical and experimental procedure.(22) Briefly, the intrathoracic inferior vena 
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cava (IVC) was excised and interposed into the infrarenal abdominal aorta in C57BL/6 
mice. Experimental groups included wild type IVC transposed into wild type aorta (WT 
WT), wild type IVC transposed into Eph-B4 knockout aorta (WT KO), Eph-B4 knockout 
IVC transposed into wild type aorta (KO WT), and Eph-B4 knockout IVC transposed 
into Eph-B4 knockout aorta (KO KO). Other experimental groups included wild type 
IVC transposed into wild type aorta along with systemic stimulation every 48 hours with 
either Ephrin-B2/Fc or control cd6/Fc. 4 weeks after the procedure, vein grafts were 
excised and sectioned. Vein graft sections were obtained from said lab member and 
Masson’s Trichrome stain was performed on all sections by the pathology lab staff at 
Yale School of Medicine. Quantification of collagen (blue) within the vascular wall as 
well as lumen circumference were done utilizing Photoshop and ImageJ software, after 
blinding by a fellow lab member. Total area of blue within the venous wall was divided 
by inner luminal circumference in order to determine average thickness of collagen in 
each vein graft wall. 
 
Cell Transfection and Eph-B4 Stimulation 
COS cells were plated in antibiotic-free growth medium (DMEM, 10% FBS, L-
glut) and grown to confluence. Media in the cell plate was then removed and replaced 
with 1ug of specified plasmids was mixed with 2ul of Lipofectamine 2000 (Life 
Technologies) in OptiMEM media (Life Technologies), per manufacturer’s protocol. For 
double transfections, 1ug of each plasmid was added. Transfected plasmids included 
eNOS, hemagglutinin-tagged Eph-B4, hemagglutinin-tagged Eph-B4 774 mutant (E-
774), pcDNA13 (control vector plasmid for eNOS), p-shuttle (control vector plasmid for 
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Eph-B4 and E-774). Cells were then incubated for 6 hours in a 37º CO2 incubator, 
followed by replacement of media with serum-free, antibiotic-free medium (DMEM, L-
glut). After continued incubation at 37º for 24 hours, stimulation experiments with 
Ephrin-B2/Fc or control cd6/Fc were performed as previously described, followed by 
extraction of cell lysates in RIPA buffer containing phosphatase-inhibitors NaF and 
Sodium Orthovanadate. Protein quantification and western blotting was then performed 
as previously described, with anti-HA (hemagglutinin) used to detect Eph-B4 due to 
antibody quality. After densitometric measurement of band size, ratio of phospho-eNOS 




For all experiments for which n ≥ 4, statistical analysis was performed by 
comparison of treatment groups with control group utilizing a 1 sample t-test or an 
independent, 2-sample t-test, with p < 0.05 considered significant. All bar graphs 
represent sample means with error bars representing standard errors of the means in 








Selection of Cells for ECM Experiments 
To select cells for use for cell culture experiments, we performed measurements 
of mRNA and protein expression of Eph-B4 at baseline in various cell types. For 
experiments on extracellular matrix deposition, an immortalized fibroblast cell line was 
desired, given that ECM deposition is a known function of fibroblasts, while the 
involvement of endothelial cells on ECM deposition is unclear. In order to determine the 
role of Eph-B4 on ECM deposition, a cell line that expresses Eph-B4 at baseline was 
required. Mouse embryonic fibroblasts (MEFs) express both Eph-B4 protein and mRNA 
at baseline, compared to positive controls (MLECs) and negative controls (COS cells, 
mouse muscle tissue) (Figure 4A, C). MEF expression of Eph-B4 normalized to GAPDH 
was 35-fold higher than negative control mouse muscle tissue, although it was not as high 
as MLEC expression of Eph-B4 (286-fold higher than mouse muscle tissue) (Figure 4C). 
Protein expression of Eph-B4 paralleled this trend (Figure 4A). Thus, MEFs were 
selected for all ECM experiments. Of note, all cell types studied expressed Ephrin-B2 at 
baseline (Figure 4B). 
 
Eph-B4 has no effect on mRNA expression of various ECM-related products 
To examine the effect of Eph-B4 stimulation on ECM deposition and remodeling, 
MEFs were stimulated with Ephrin-B2/Fc or control IgG/Fc for various durations, 
followed by quantification of mRNA expression of various ECM-related products. 
Stimulation of Eph-B4 in MEFs with Ephrin-B2/Fc or IgG/Fc had no effect on mRNA 
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expression of Collagen I, Collagen III, MMP2, and MMP9 after 4 hours or 12 hours (n=2 
for each group) (Figure 5A). Similarly, stimulation of Eph-B4 in MEFs had no effect on 
mRNA expression of MMP14, elastin, TIMP1 and TIMP2 after 4 hours or 24 hours (n=3 
for each group) (Figure 5B).  
In order to study changes in extracellular matrix production which may occur over 
a longer time course of days, we further extended the period of stimulation to up to 5 
days in culture. Compared to control cells at the beginning of the stimulation period 
(n=1), all cell culture groups – Unstimulated, Ephrin-B2/Fc, Cd6/Fc (n=2 for each group) 
– displayed increased mRNA expression of collagen I, collagen III, MMP2, and MMP9 
that peaked for each product by the 3rd day of stimulation. This increase was maintained 
up to the 5th day for MMP2, but returned to baseline for all other products (Figure 5C). 
Most notably, there was no difference in the pattern of mRNA expression at any point 
during the 5 day duration between the Ephrin-B2/Fc stimulated samples and the samples 
in the two control groups, for all 4 products. 
Finally, we examined the effect of Ephrin-B2/Fc stimulation on collagen 
expression of ex vivo human saphenous vein grafts in culture. There was no change in the 
mRNA expression of Collagen I in the Ephrin-B2/Fc stimulated group after 21 days of 
stimulation compared to either the unstimulated group (p=0.948) or the Day 0 uncultured 
group (p=0.834) (n=7 for each group) (Figure 5D).  
 




 To examine total collagen deposition, we measured total collagen deposited onto 
cell plate walls by MEFs. There was no significant difference in total collagen deposited 
after 7-8 days, utilizing the Sircol Collagen Assay (n=6) (p=0.127) (Figure 6A). There 
was also no difference in total MMP2 and MMP9 intracellular protein expression 
between stimulated and unstimulated cells, as measured by Western Blot of the cell 
lysates (n=2-3) (Figure 6B) after both 6 and 48 hours, although total MMP2 and MMP9 
did increase with additional time of culture, corresponding to their mRNA levels, as 
described above. Negligible elastin protein expression was identified in all samples (data 
not shown). 
 We then examined the total activity of MMP2 intracellularly and within 
conditioned media by zymography. There was no change in total MMP2 activity within 
the conditioned media of the cells after 6 hours of stimulation (which accounts for 
secretion of MMP2 by cells and degree of activation/post translational modification) 
(p=.481, n=3-4) (Figure 7A-B). The results were similar with normalization of 
zymography densitometry to either total protein in each sample or to approximate cell 
number within each sample (data not shown). Likewise, there was no change in total 
MMP2 activity within the cell lysates after either 6 hours or 48 hours of stimulation 
(which accounts for protein expression by cells and degree of activation/post-translational 
modification) (Figure 7C).  
 
Eph-B4 has no effect on overall collagen deposition in mouse vein grafts 
To examine the effect of Eph-B4 on vein grafts, veins from wild type (WT) or 
Eph-B4 knockout (KO) mice were grafted into the aortas of wild type or Eph-B4 
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knockout mice. After 4 weeks, vein grafts were sectioned and stained with Masson’s 
Trichrome to quantify total collagen present within vein graft walls. Blue-staining 
collagen was mostly apparent in the adventitial layer, with the combined mouse intima-
media layer containing both red and blue (Figure 8A). There was no difference in 
average thickness of the collagen blue in the vein graft walls among any of the four 
knockout groups compared to control WT WT – WT KO (p=0.697), KO WT (p=0.937), 
KO KO (p=0.215) (n=4-5 for each group) (Figure 8B). There was also no significant 
difference in average lumen circumference of the vein graft between any of the 3 groups 
compared to control WT WT (p>0.088 for all 3 groups) (n=4 per group) (Figure 8B).  
To confirm these results, a similar experiment was performed in which wild type 
vein grafts were interposed into the aortas of wild type mice (WT WT), but with half the 
group undergoing stimulation with systemic Ephrin-B2/Fc or control Cd6/Fc. In this 
case, there was no difference in average thickness of the collagen blue in the vein graft 
wall (p=0.808) and no difference in average lumen circumference (p=0.636) between the 
two groups (n=3-4 per group) (Figure 8C). 
 
Eph-B4 interacts directly with eNOS to produce eNOS phosphorylation 
Since Eph-B4 does not appear to regulate vein graft adaptation by regulation of 
ECM volume or components, we next examined whether regulation of eNOS would be a 
potential mechanism of Eph-B4 action.	  For experiments on the interaction of Eph-B4 and 
eNOS, a cell line that exhibits high transfection efficiency yet does not express Eph-B4 
and eNOS at baseline is required. COS cells do not express Eph-B4 or eNOS protein at 
28	  
	  
baseline (Figure 4A, Figure 9A, Figure 10A), and do not express Eph-B4 mRNA at 
baseline (from prior lab members, data not shown). 
COS cells were transfected with either Eph-B4, eNOS, both, or the combination 
of the vector plasmids (P-S and pcDNA). Confirmation of transfection is shown in 
Figure 9A, where only cells with transfected plasmid expressed that product on Western 
Blot. The results strongly suggest a direct interaction between Eph-B4 and eNOS. The 
proportion of phosphorylated transfected eNOS is massively increased simply by the 
simultaneous transfection of Eph-B4, without requiring Eph-B4 stimulation. Stimulation 
of Eph-B4 with Ephrin-B2/Fc then increased this proportion even further. As expected, 
stimulation with Ephrin-B2/Fc in the absence of simultaneous Eph-B4 transfection did 
not increase the proportion of phosphorylated eNOS (Figure 9B). A dual peak of eNOS 
phosphorylation is apparent with a rapid early peak after 1-5 mins of stimulation and a 
later peak beginning at 30 mins of stimulation (Figure 9C). This bimodal distribution 
exactly matches that seen in our preliminary data within MLECs (data by prior lab 
members, data not shown). 
 
Tyrosine 774 affects but is not critical to Eph-B4’s interaction with eNOS 
Given that a mutation in Tyrosine 774 abolishes Eph-B4’s effect on Akt 
phosphorylation, we repeated the transfection experiments utilizing a mutation in Eph-B4 
at tyrosine 774 (E-774). As previously, confirmation of transfection is shown in Figure 
10A. E774 did not abolish Eph-B4’s ability to phosphorylate eNOS, as the proportion of 
phosphorylated transfected eNOS is increased, again, simply by the simultaneous 
transfection of E774 with eNOS, followed by a further increase upon stimulation of E774 
29	  
	  
with Ephrin-B2/Fc (Figure 10B). Similarly, the dual-peaked temporal pattern of eNOS 
phosphorylation upon Eph-B4 stimulation is preserved (Figure 10C). 
However, although increased, these amount of these increases is substantially less 
than the increases observed with transfection and stimulation of wild-type Eph-B4. 
Simultaneous transfection with either WT Eph-B4 or E-774 both led to an approximately 
3.8-fold increase in proportion of phosphorylated transfected eNOS. However, further 
stimulation with Ephrin-B2/Fc led to a smaller increase in E774 (4.4-fold) compared to 
that in wild type Eph-B4 (Figures 9B, 10B). Similarly, although the dual-peaked 
temporal pattern is preserved, the peaks are diminished and delayed. The early peak, 
which began as early as after 1 minute of stimulation with a max increase in 
phosphorylated eNOS of 6.6-fold, is delayed, only appearing after 5 minutes of 
stimulation and with a max increase of only 4.4-fold. Similarly, the later peak, which 
began as early as after 30 minutes of stimulation with a maximum of 5.9-fold increase in 
phosphorylated eNOS in the WT Eph-B4 transfections, is delayed to sometime after 30 
minutes, with a maximum measured increase of 4.7-fold in E774 (Figures 9C, 10C). 
Thus, unlike Eph-B4’s relationship with Akt, the presence of tyrosine 774 affects Eph-








Vein graft failure due to neointimal hyperplasia continues to be a significant 
source of patient morbidity and mortality, while being a significant siphon to healthcare 
expenditure in the United States. Thus far, advances in knowledge of vascular biology 
has led to many prospective therapies to fix this problem, but thus far none have 
successfully translated clinically, and we are continually looking for new ways to control 
the optimal amount of vein wall thickening necessary for proper adaptation to the arterial 
environment without the stenosis that occurs with pathological, over-exuberant wall 
thickening. 
Vein wall thickening requires both cell proliferation and extracellular matrix 
deposition (13, 26, 27). The receptor tyrosine kinase Eph-B4, an embryologic 
determinant of venous identity, is not only a marker of venous identity in adulthood but 
appears to continue to influence vascular plasticity, as vein grafts lose their venous 
identity but does not gain an arterial identity as part of the adaptation process to the 
arterial environment, while stimulation of Eph-B4 results in decreased vein graft wall 
thickening (1, 22). However, we do not currently know the mechanism by which Eph-B4 
mediates any of its downstream effects. Given the importance of extracellular matrix 
deposition and remodeling to vein graft adaptation, we sought to determine whether Eph-
B4 accomplishes its effect of by decreasing extracellular matrix deposition and 
remodeling, in order to better understand how to it can be utilized as a potential 
therapeutic target in clinical trials in the future for the pharmacological control of vein 
graft stenosis and failure. 
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Through a series of in vitro, in vivo, and ex vivo experiments, we have shown that 
Eph-B4 has little effect on ECM deposition and remodeling. Stimulation of Eph-B4 led to 
no changes in mRNA expression of Collagen I, Collagen III and elastin, at both early and 
late timepoints. Of note, Collagen I and Collagen III were selected among the myriad 
collagens as they are the collagens most prevalent in the vascular system and most 
responsible for both tensile strength and elasticity (45). Similarly, stimulation of Eph-B4 
led to no changes in mRNA expression of MMP2 and MMP9, the two matrix 
metalloproteinases most often implicated in vascular remodeling, as well as TIMP1 and 
TIMP2, the major regulators of MMP activity. Ex vivo, human saphenous veins displayed 
no alterations in collagen mRNA expression following 14 days of Eph-B4 stimulation in 
culture. Paralleling the lack of effect on collagen-related mRNA products, Eph-B4 
stimulation also had no effect on cellular protein expression of MMP2 and MMP9, no 
effect on total collagen secreted by cells, and no effect on total secreted and intracellular 
MMP2 activity as measured by gelatin zymography, where total activity additionally 
accounts for protein expression, active cellular secretion, and post-translational activation 
of MMP2. 
The study of extracellular matrix is vast, and this study is limited in the aspects of 
ECM deposition and remodeling that can be studied. For example, there are at least 19 
collagens identified, while 13 of them can be found in the vascular wall (45). Many other 
related molecules, such as elastin and proteoglycans, may also play a significant role in 
remodeling the caliber and elasticity of the vascular wall. Additionally, the degradation of 
collagen not only involves more than 24 classes of matrix metalloproteinases, but also 
other related molecules such as a variety of cathepsins and elastases (46, 47). There are 
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also at least four known mammalian TIMPs (48). Finally, as previously mentioned, other 
related signaling pathways, like TGF-β, also play a very significant role, and the 
interaction between all of these components are complex. We focused our experiments on 
only the components that were most prominent within vascular remodeling (Collagen I, 
Collagen III, elastin, MMP2, MMP9, MMP14, TIMP1, TIMP2), and a completely 
thorough examination of Eph-B4 expression on all aspects of ECM 
deposition/remodeling would be difficult. Although it is possible that Eph-B4 may affect 
the expression and activity of some of these other components, our in vivo mouse studies, 
in which Eph-B4 stimulation resulted in no significant histological difference in overall 
collagen deposition into the walls of the vein graft, suggests that this is unlikely.  
Another limitation of the extracellular matrix experiments is that a majority of the 
molecular studies were performed on cells or veins in culture, which may not be 
representative of a vein graft in vivo. Furthermore, the experiments utilized only a few, 
selected time points thought to be representative, while true changes in mRNA and 
protein expression and activity may occur at any number of time points that were not 
measured. However, again, despite these limitations, our in vivo results showing no 
overall change in collagen deposition 4 weeks after vein graft implantation provides 
confirmation of our molecular studies within culture. 
Inspection of the vein graft sections after Trichrome staining revealed that the 
majority of blue-staining collagen seemed to be present within the adventitia, and only 
some collagen present in the intima-media layer. Combined with previous studies 
suggesting that it is the thickness of the neointimal layer that is affected by Eph-B4 (22), 
these results suggest that Eph-B4 likely reduces vein wall thickening not through 
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reducing extracellular matrix deposition, but mainly through decreasing smooth muscle 
cell proliferation and migration within the intima, which should be the main focus of 
future studies on the mechanism of Eph-B4. 
Finally, we were able to demonstrate a direct interaction between Eph-B4 and 
eNOS. Although our preliminary data had shown that Eph-B4 induced a dual-peak of 
phosphorylation of eNOS within MLECs, it was not determined whether this effect was a 
direct interaction between the two or whether this was an indirect effect. We were able to 
demonstrate a very similar dual-peaked temporal profile of eNOS phosphorylation after 
Eph-B4 stimulation within transfected COS cells. Furthermore, we were able to show that 
transfection of Eph-B4, even without further stimulation, is enough to greatly increase the 
amount of eNOS phosphorylation. By demonstrating this data in a transfected cell line 
that has no inherent expression of Eph-B4 and eNOS and thus likely has little of the 
associated cellular machinery associated with the two, these results strongly suggest a 
direct interaction between Eph-B4 and eNOS within the cell, with eNOS likely directly 
mediating many of Eph-B4’s downstream effects. 
Furthermore, we replicated the double transfection experiments with a version of 
Eph-B4 containing a mutation of Tyrosine 774 (Tyrosine  Phenylalanine). In our 
search for the critical tyrosines that mediates either Eph-B4 auto-phosphorylation or its 
downstream phosphorylation functions, tyrosine 774 has been previously implicated by 
our lab as one such critical tyrosine. Although we have shown that this exact Y774F 
mutation leads to abolishment of the phosphorylation of Akt, one of the downstream 
effectors of Eph-B4, it was unknown whether this mutation led to an isolated decrease in 
the phosphorylation of Akt by Eph-B4, or whether the mutation leads to a complete 
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destruction of all Eph-B4 activity, either through inducing a complete protein misfolding 
or through destroying the Eph-B4 receptor’s ability to auto-phosphorylate and activate 
itself upon encountering its ligand.  
By demonstrating that the Y774F mutation preserves the effect of Eph-B4 on 
eNOS phosphorylation, our results suggest that tyrosine 774 is not crucial to all Eph-B4 
downstream function, is not required for Eph-B4 self-activation, and that Y774F does not 
induce a global protein misfolding. These results also suggest that tyrosine 774 is likely 
the crucial tyrosine specifically for Eph-B4’s interaction with Akt. Although we did 
observe a minor diminishment of total eNOS phosphorylation and a minor delay in the 
two peaks of phosphorylation, the most likely explanation is that although tyrosine 774 is 
not crucial to Eph-B4’s interaction with eNOS, the mutation leads to minor 
conformational changes that result in a slightly decreased efficiency of the Eph-B4 
receptor. Future studies will look to further examine the other remaining tyrosines to 
determine the crucial tyrosine(s) responsible for the interaction of Eph-B4 and eNOS, as 
well as the tyrosine(s) responsible for Eph-B4 auto-phosphorylation and activation. 
Several other tyrosines have already been established by our lab as potentially important 
targets, such as tyrosines 821 and 924. As eNOS may mediate a large variety of 
important vascular functions, future studies will also examine which of the downstream 
effects of Eph-B4 is mediated specifically by eNOS. Since Eph-B4 does not affect ECM 
deposition but instead targets eNOS, future in vitro molecular studies on Eph-B4 should 
be performed on endothelial cells (mediators of signaling and from which eNOS is 
secreted) rather than the fibroblasts used in these experiments. 
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In conclusion, Eph-B4 stimulation has little effect on extracellular matrix 
deposition, specifically not on the expression and activity of collagen I, collagen III, 
MMP2, MMP9, MMP14, elastin, TIMP1, TIMP2, and not on overall collagen deposition 
by fibroblast cells in vitro and mouse vein graft walls in vivo. Eph-B4’s effects on 
decreasing vein wall thickening likely occurs through modulation of vascular smooth 
muscle proliferation and migration instead. Furthermore, Eph-B4 likely interacts directly 
with eNOS to mediate some of its downstream effects, and tyrosine 774, although crucial 
to the interaction of Eph-B4 with Akt, is not crucial for global function of Eph-B4 or the 
interaction of Eph-B4 with eNOS. 
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FIGURES AND LEGENDS 
 
Figure 4. Baseline expression of A) Eph-B4 (~120 kDA) and B) Ephrin-B2 (~55 
kDA) in multiple cell types. C) mRNA expression of Eph-B4. MEF = Mouse 
Embryonic Fibroblasts, MLEC = Mouse Lung Endothelial Cells, COS = cos-7 










Figure 5. mRNA Expression of Collagen-related products after stimulation of Eph-
B4. A) Expression of collagen-related products in MEFs after 4 hours (upper panel) or 12 
hours (lower panel) of stimulation with control IgG/Fc or Ephrin-B2/Fc, normalized to 
the unstimulated expression, n=2. B) Expression of additional products after 4 hours 
(upper panel) or 24 hours (lower panel). C) Expression of collagen-related products in 
MEFs after up to 5 days of stimulation with control IgG/Fc or Ephrin-B2/Fc (n=2), 
normalized to MEF isolated at the beginning of the experiment (n=1). D) Expression of 
collagen I in untreated or Ephrin-B2/Fc treated human veins in culture after 14 days, with 
each sample normalized to corresponding uncultured Day 0 human vein (n=7 for each 
group). Col1a1 = Type I Collagen, Col3a1 = Type III Collagen, MMP = Matrix 




















Figure 6. Protein expression of collagen-related products after stimulation of MEFs 
in culture. A) Total collagen secreted onto the cell culture plate (n=6), normalized to 
control group. B) Western Blot of MMP2 and MMP9 within MEF cell lysates after 6 











Figure 7. Activity of MMP-2 and MMP-9 measured by zymography after 
stimulation of Eph-B4 with Ephrin-B2/Fc in MEFs. A) Zymography of MMP-2 
activity in conditioned media of (secreted by) unstimulated (U, n=4) and stimulated (E, 
n=3) cells. B) Densitometry comparisons of bands representing MMP-2 activity in 
conditioned media (secreted by) stimulated and unstimulated cells. C) Densitometry 












Figure 8. Histological quantification of total collagen and lumen circumference 
within Masson’s Trichrome stains of sections of vein grafts in mice. A) Sample 
Trichrome stain of vein graft section. B) Average wall thickness and lumen 
circumference of 4 week old vein grafts in Eph-B4 knockout experiment. C) Average 
wall thickness and lumen circumference of 4 week old vein grafts in Eph-B4 stimulation 











Figure 9. Eph-B4 and eNOS transfection within COS cells. A) Eph-B4, eNOS, or both 
were transfected into COS cells, stimulated with designated ligand, and cell lysates were 
taken for Western blot to measure Eph-B4, total eNOS, or phospo-eNOS. B) 
Densitometry quantification of ratio of p-eNOS to total eNOS. C) Densitometry 
quantification of ratio of p-eNOS to total eNOS, normalized to ratio in unstimlated 
samples. PS = P-Shuttle (vector control for Eph-B4 plasmid). pcDNA = pcDNA13 
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Figure 10. Eph-B4 mutant E-774 and eNOS transfection within COS cells. A) E-774, 
eNOS, or both were transfected into COS cells, stimulated with designated ligand, and 
cell lysates were taken for Western blot to measure E774, total eNOS, or phospo-eNOS. 
B) Densitometry quantification of ratio of p-eNOS to total eNOS. C) Densitometry 
quantification of ratio of p-eNOS to total eNOS, normalized to ratio in unstimulated 
samples. PS = P-Shuttle (vector control for E-774 plasmid). pcDNA = pcDNA13 (vector 
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